Innovative Contracting | Cell & Gene Therapies
Pharmaceutical companies and payers in the UK, US and Germany are increasingly signing Pay for Performance (P4P) contracts. Many of these contracts deal with cell and gene therapies. Post-launch evidence generation through registries is another topic of high interest. This first session of MAP’s “Meet the Experts” series discussed these areas, welcoming experts from the German landscape including: Dr. Barthold Dieters as a representative of GWQ who has signed several P4P contracts in the past; Dr. Alexander Natz, Secretary General, EUCOPE; and Dr. Peter Lütkes, a hospital controller who is familiar with hospital reimbursement for high priced medicines. The meeting was a great success, with fascinating insights and some thought provoking questions.